The company had posted a net profit of Rs 18.59 crore for the corresponding period of previous fiscal, Aarti Drugs said in a BSE filing.
However, consolidated total revenue of the company stood at Rs 301.08 crore as against Rs 314.61 crore for the same period year ago.
For the fiscal year ended March 31, 2017, the net profit of the company was at Rs 80.56 crore. It was Rs 68.72 crore in the year-ago period.
In a separate filing, the company said its board has recommended a final dividend of Re 1 per equity share of Rs 10 for the financial year ended March 31, 2017.
Shares of the company closed 2.79 per cent down at Rs 515.15 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
